83.78
price down icon1.10%   -0.93
after-market  After Hours:  83.79  0.01   +0.01%
loading
Biomarin Pharmaceutical Inc. stock is currently priced at $83.78, with a 24-hour trading volume of 28.15M. It has seen a -1.10% decreased in the last 24 hours and a +8.33% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $84.35 pivot point. If it approaches the $83.42 support level, significant changes may occur.
Previous Close:
$84.71
Open:
$85.73
24h Volume:
28.15M
Market Cap:
$15.91B
Revenue:
$2.47B
Net Income/Loss:
$205.46M
P/E Ratio:
108.99
EPS:
0.7687
Net Cash Flow:
$163.21M
1W Performance:
+0.32%
1M Performance:
+8.33%
6M Performance:
-11.96%
1Y Performance:
-13.04%
1D Range:
Value
$82.44
$85.73
52W Range:
Value
$73.67
$99.56

Biomarin Pharmaceutical Inc. Stock (BMRN) Company Profile

Name
Name
Biomarin Pharmaceutical Inc.
Name
Phone
415-506-6700
Name
Address
770 Lindaro Street, San Rafael, CA
Name
Employee
2,581
Name
Twitter
Name
Next Earnings Date
2024-05-21
Name
Latest SEC Filings
Name
BMRN's Discussions on Twitter

Biomarin Pharmaceutical Inc. Stock (BMRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-15-23 Initiated Wells Fargo Overweight
Oct-23-23 Upgrade Bernstein Underperform → Mkt Perform
Sep-28-23 Initiated Raymond James Mkt Perform
Sep-18-23 Initiated UBS Buy
Jul-27-23 Initiated Scotiabank Sector Perform
Jul-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-14-23 Resumed Credit Suisse Outperform
Mar-21-23 Initiated Bernstein Underperform
Feb-22-23 Downgrade Oppenheimer Outperform → Perform
Feb-21-23 Initiated Citigroup Neutral
Jan-30-23 Initiated BMO Capital Markets Market Perform
Jan-18-23 Initiated Canaccord Genuity Hold
Oct-31-22 Upgrade Oppenheimer Perform → Outperform
Jul-13-22 Initiated Cantor Fitzgerald Overweight
Jun-13-22 Resumed Wedbush Neutral
Apr-25-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-22-21 Upgrade William Blair Mkt Perform → Outperform
Oct-07-21 Resumed Jefferies Buy
Sep-09-21 Upgrade Stifel Hold → Buy
Jun-04-21 Resumed Robert W. Baird Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Mar-04-21 Resumed Guggenheim Buy
Mar-01-21 Upgrade Evercore ISI In-line → Outperform
Aug-20-20 Downgrade Citigroup Buy → Neutral
Aug-20-20 Downgrade William Blair Outperform → Mkt Perform
Aug-19-20 Downgrade Evercore ISI Outperform → In-line
Aug-19-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20 Downgrade Stifel Buy → Hold
Jul-08-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-06-20 Reiterated Citigroup Buy
Jan-28-20 Initiated BMO Capital Markets Market Perform
Jan-27-20 Initiated BMO Capital Markets Market Perform
Jan-24-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-27-19 Upgrade Barclays Equal Weight → Overweight
Nov-12-19 Initiated SunTrust Buy
Oct-17-19 Resumed BofA/Merrill Buy
May-23-19 Resumed Citigroup Buy
Apr-09-19 Resumed Raymond James Outperform
Jan-02-19 Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18 Initiated Wolfe Research Outperform
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-07-18 Reiterated Stifel Buy
Aug-03-18 Reiterated Stifel Buy
View All

Biomarin Pharmaceutical Inc. Stock (BMRN) Financials Data

Biomarin Pharmaceutical Inc. (BMRN) Revenue 2024

BMRN reported a revenue (TTM) of $2.47 billion for the quarter ending March 31, 2024, a +13.74% rise year-over-year.
loading

Biomarin Pharmaceutical Inc. (BMRN) Net Income 2024

BMRN net income (TTM) was $205.46 million for the quarter ending March 31, 2024, a +186.89% increase year-over-year.
loading

Biomarin Pharmaceutical Inc. (BMRN) Cash Flow 2024

BMRN recorded a free cash flow (TTM) of $163.21 million for the quarter ending March 31, 2024, a +649.72% increase year-over-year.
loading

Biomarin Pharmaceutical Inc. (BMRN) Earnings per Share 2024

BMRN earnings per share (TTM) was $1.07 for the quarter ending March 31, 2024, a +182.55% growth year-over-year.
loading

Biomarin Pharmaceutical Inc. Stock (BMRN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
MEIER RICHARD A
Director
Jun 03 '24
Option Exercise
63.10
6,600
416,460
126,227
HERON ELAINE J
Director
Jun 03 '24
Option Exercise
63.10
5,047
318,466
101,888
Mueller Brian
EVP, Chief Financial Officer
May 30 '24
Option Exercise
63.10
5,000
315,500
77,159
Mueller Brian
EVP, Chief Financial Officer
May 30 '24
Sale
75.19
5,000
375,950
72,159
Davis George Eric
EVP, Chief Legal Officer
May 28 '24
Option Exercise
63.10
40,850
2,577,635
97,007
Davis George Eric
EVP, Chief Legal Officer
May 28 '24
Sale
74.51
40,850
3,043,802
56,157
BIENAIME JEAN JACQUES
Director
May 10 '24
Option Exercise
63.10
20,000
1,262,000
494,994
BIENAIME JEAN JACQUES
Director
May 10 '24
Sale
81.14
20,000
1,622,800
474,994
BIENAIME JEAN JACQUES
Director
May 09 '24
Option Exercise
63.10
20,000
1,262,000
494,994
BIENAIME JEAN JACQUES
Director
May 09 '24
Sale
81.62
20,000
1,632,400
474,994
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
$156.11
price up icon 0.37%
$26.03
price up icon 0.58%
$84.64
price down icon 1.44%
$165.70
price up icon 5.27%
$394.47
price up icon 1.70%
Cap:     |  Volume (24h):